---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-21-000020"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T00:44:44.768889+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edwards Q2 sales $1.4B (+49% YoY); raises FY2021 sales & adjusted EPS guidance

## Summary
- Q2 2021 sales $1.4B, up 49% reported (44% underlying); diluted EPS $0.78, adjusted EPS $0.64.
- TAVR sales $902M (+52% reported, +48% underlying); FY2021 TAVR growth guidance raised to ~20%.
- Full-year 2021 sales guidance raised to $5.2–$5.4B (from $4.9–$5.3B); adjusted EPS guided to high end of $2.07–$2.27.
- Q3 2021 guidance: sales $1.29–$1.37B, adjusted EPS $0.50–$0.56.
- Free cash flow $457M; cash $2.6B; repurchased 1.3M shares for $112M in Q2.

## SEC filing metadata
- accession: 0001099800-21-000020
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980021000020/0001099800-21-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980021000020/ew-20210729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-21-000020
- JSON: https://secwatch.observer/filing/0001099800-21-000020.json
- Plain text: https://secwatch.observer/filing/0001099800-21-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.